257 related articles for article (PubMed ID: 31628266)
1. Contextualizing the Use of Moxetumomab Pasudotox in the Treatment of Relapsed or Refractory Hairy Cell Leukemia.
Kreitman RJ; Pastan I
Oncologist; 2020 Jan; 25(1):e170-e177. PubMed ID: 31628266
[TBL] [Abstract][Full Text] [Related]
2. Moxetumomab pasudotox in heavily pre-treated patients with relapsed/refractory hairy cell leukemia (HCL): long-term follow-up from the pivotal trial.
Kreitman RJ; Dearden C; Zinzani PL; Delgado J; Robak T; le Coutre PD; Gjertsen BT; Troussard X; Roboz GJ; Karlin L; Gladstone DE; Kuptsova-Clarkson N; Liu S; Patel P; Rotolo F; Mitry E; Pastan I; Giles F;
J Hematol Oncol; 2021 Feb; 14(1):35. PubMed ID: 33627164
[TBL] [Abstract][Full Text] [Related]
3. Immunoconjugates in the management of hairy cell leukemia.
Kreitman RJ; Pastan I
Best Pract Res Clin Haematol; 2015 Dec; 28(4):236-45. PubMed ID: 26614902
[TBL] [Abstract][Full Text] [Related]
4. Moxetumomab pasudotox-tdfk for relapsed/refractory hairy cell leukemia: a review of clinical considerations.
Nobre CF; Newman MJ; DeLisa A; Newman P
Cancer Chemother Pharmacol; 2019 Aug; 84(2):255-263. PubMed ID: 31134324
[TBL] [Abstract][Full Text] [Related]
5. Development of Recombinant Immunotoxins for Hairy Cell Leukemia.
Kreitman RJ; Pastan I
Biomolecules; 2020 Aug; 10(8):. PubMed ID: 32756468
[TBL] [Abstract][Full Text] [Related]
6. Moxetumomab pasudotox for the treatment of relapsed and/or refractory hairy cell leukemia.
Abou Dalle I; Ravandi F
Expert Rev Hematol; 2019 Sep; 12(9):707-714. PubMed ID: 31298972
[No Abstract] [Full Text] [Related]
7. Minimal residual hairy cell leukemia eradication with moxetumomab pasudotox: phase 1 results and long-term follow-up.
Kreitman RJ; Tallman MS; Robak T; Coutre S; Wilson WH; Stetler-Stevenson M; FitzGerald DJ; Santiago L; Gao G; Lanasa MC; Pastan I
Blood; 2018 May; 131(21):2331-2334. PubMed ID: 29487070
[TBL] [Abstract][Full Text] [Related]
8. Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia.
Kreitman RJ; Dearden C; Zinzani PL; Delgado J; Karlin L; Robak T; Gladstone DE; le Coutre P; Dietrich S; Gotic M; Larratt L; Offner F; Schiller G; Swords R; Bacon L; Bocchia M; Bouabdallah K; Breems DA; Cortelezzi A; Dinner S; Doubek M; Gjertsen BT; Gobbi M; Hellmann A; Lepretre S; Maloisel F; Ravandi F; Rousselot P; Rummel M; Siddiqi T; Tadmor T; Troussard X; Yi CA; Saglio G; Roboz GJ; Balic K; Standifer N; He P; Marshall S; Wilson W; Pastan I; Yao NS; Giles F
Leukemia; 2018 Aug; 32(8):1768-1777. PubMed ID: 30030507
[TBL] [Abstract][Full Text] [Related]
9. Treatment of hairy cell leukemia.
Chihara D; Kreitman RJ
Expert Rev Hematol; 2020 Oct; 13(10):1107-1117. PubMed ID: 32893700
[TBL] [Abstract][Full Text] [Related]
10. Moxetumomab pasudotox for the treatment of hairy cell leukemia.
Janus A; Robak T
Expert Opin Biol Ther; 2019 Jun; 19(6):501-508. PubMed ID: 31045462
[No Abstract] [Full Text] [Related]
11. Moxetumomab Pasudotox in Hairy Cell Leukaemia: A Profile of Its Use.
Kang C
Clin Drug Investig; 2021 Sep; 41(9):829-834. PubMed ID: 34383256
[TBL] [Abstract][Full Text] [Related]
12. Diagnosis and treatment of hairy cell leukemia as the COVID-19 pandemic continues.
Kreitman RJ; Arons E
Blood Rev; 2022 Jan; 51():100888. PubMed ID: 34535326
[TBL] [Abstract][Full Text] [Related]
13. Moxetumomab pasudotox for hairy cell leukemia: preclinical development to FDA approval.
Lin AY; Dinner SN
Blood Adv; 2019 Oct; 3(19):2905-2910. PubMed ID: 31594764
[TBL] [Abstract][Full Text] [Related]
14. Hairy cell leukemia: present and future directions.
Kreitman RJ
Leuk Lymphoma; 2019 Dec; 60(12):2869-2879. PubMed ID: 31068044
[TBL] [Abstract][Full Text] [Related]
15. Recombinant immunotoxins and other therapies for relapsed/refractory hairy cell leukemia.
Kreitman RJ; Arons E; Stetler-Stevenson M; Fitzgerald DJ; Wilson WH; Pastan I
Leuk Lymphoma; 2011 Jun; 52 Suppl 2(Suppl 2):82-6. PubMed ID: 21599609
[TBL] [Abstract][Full Text] [Related]
16. Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia.
Kreitman RJ; Tallman MS; Robak T; Coutre S; Wilson WH; Stetler-Stevenson M; Fitzgerald DJ; Lechleider R; Pastan I
J Clin Oncol; 2012 May; 30(15):1822-8. PubMed ID: 22355053
[TBL] [Abstract][Full Text] [Related]
17. Moxetumomab pasudotox: A first-in-class treatment for hairy cell leukemia.
Fancher KM; Lally-Montgomery ZC
J Oncol Pharm Pract; 2019 Sep; 25(6):1467-1472. PubMed ID: 30917739
[TBL] [Abstract][Full Text] [Related]
18. Hairy cell leukemia-new genes, new targets.
Kreitman RJ
Curr Hematol Malig Rep; 2013 Sep; 8(3):184-95. PubMed ID: 23892906
[TBL] [Abstract][Full Text] [Related]
19. Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotox.
Kreitman RJ; Pastan I
Clin Cancer Res; 2011 Oct; 17(20):6398-405. PubMed ID: 22003067
[TBL] [Abstract][Full Text] [Related]
20. 5-Azacytidine prevents relapse and produces long-term complete remissions in leukemia xenografts treated with Moxetumomab pasudotox.
Müller F; Cunningham T; Stookey S; Tai CH; Burkett S; Jailwala P; Stetler Stevenson M; Cam MC; Wayne AS; Pastan I
Proc Natl Acad Sci U S A; 2018 Feb; 115(8):E1867-E1875. PubMed ID: 29432154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]